USPH · U S Physical Therapy Inc /Nv
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| IIP revenue | $27.38M | FY2025 Q1 | +28.8% |
|
|
|||
| Physical therapy net revenue | $156.41M | FY2025 Q1 | +16.4% |
|
|
|||
| Average daily visits per clinic | 31.8 | Q1 2026 | — |
| Corporate expense as a percentage of total revenue | 9.2% | Q1 2026 | — |
| IIP margin | 20.4% | Q1 2026 | — |
| Net rate per physical therapy visit | $106.49 | Q1 2026 | — |
| Patient visits | 1,543,144 | Q1 2026 | — |
| Physical therapy margin | 15.8% | Q1 2026 | — |
| Total clinic count | 783 | as of March 31, 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
USPH
this stock
U S Physical Therapy Inc /Nv
|
$1.20B | +1.8% | +16.3% | 158.0 | 6.7% |
|
HCA
HCA Healthcare, Inc.
|
$86.43B | -10.3% | +7.1% | 13.4 | 2.6% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$28.50B | -11.3% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$22.62B | +32.2% | -2.3% | 13.2 | 3.5% |
|
DVA
Davita Inc.
|
$15.17B | +110.8% | +6.5% | 22.1 | 7.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| USPH | +5.7% | +14.8% | -3.2% | +15.0% | +1.8% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | +6.7% | +14.8% | -10.7% | +15.8% | -6.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.